全文获取类型
收费全文 | 259篇 |
免费 | 13篇 |
国内免费 | 3篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 20篇 |
口腔科学 | 35篇 |
临床医学 | 18篇 |
内科学 | 94篇 |
皮肤病学 | 2篇 |
神经病学 | 19篇 |
特种医学 | 9篇 |
外科学 | 43篇 |
综合类 | 2篇 |
预防医学 | 13篇 |
眼科学 | 5篇 |
药学 | 4篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 1篇 |
2019年 | 7篇 |
2018年 | 11篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 21篇 |
2013年 | 14篇 |
2012年 | 16篇 |
2011年 | 21篇 |
2010年 | 12篇 |
2009年 | 2篇 |
2008年 | 20篇 |
2007年 | 13篇 |
2006年 | 14篇 |
2005年 | 13篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 8篇 |
2001年 | 5篇 |
2000年 | 6篇 |
1999年 | 11篇 |
1998年 | 10篇 |
1997年 | 2篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有275条查询结果,搜索用时 0 毫秒
51.
52.
Vassiliki Kotoula Kalliopi Tsakiri Georgia-Angeliki Koliou Georgios Lazaridis Kyriaki Papadopoulou Eleni Giannoulatou Ioannis Tikas Christos Christodoulou Kyriakos Chatzopoulos Mattheos Bobos George Pentheroudakis Eleftheria Tsolaki Anna Batistatou Athanassios Kotsakis Angelos Koutras Helena Linardou Evangelia Razis Eleni Res George Fountzilas 《Clinical breast cancer》2019,19(2):113-125.e4
Background
We examined tumor genotype characteristics of human epidermal growth factor receptor 2 (HER2)-positive relapsed (R-) and de novo (dn-) metastatic breast cancer (MBC) in trastuzumab-treated patients who were previously not exposed to this agent.Materials and Methods
We analyzed genotypes obtained upon deep sequencing from 113 HER2-positive primary tumors from 69 patients with R-MBC and 44 patients with dn-MBC.Results
Mutations were observed in 90 (79.6%) tumors, 56 R-MBC and 34 dn-MBC (median number per tumor: 2; mean: 11.2; range: 0-150). The top mutated gene was TP53 (63.7%) followed by PIK3CA (24.8%) and others that were mostly co-mutated with TP53 (eg, 22 of 28 PIK3CA mutated tumors were co-mutated in TP53, 17 of these were R-MBC [P = .041]). dn-MBC had higher CEN17 average copies (P = .048). Tumor mutational burden inversely correlated with average HER2 copies (rho ?0.32; P < .001). In all patients, PIK3CA mutations and higher proliferation rate were independent unfavorable prognosticators. In R-MBC, longer disease-free interval between initial diagnosis and relapse conferred lower risk for time-to-progression (P < .001) and death (P = .009); PIK3CA mutations conferred higher risk for death (P = .035). In dn-MBC, surgical removal of the primary tumor before any other therapy was favorable for time-to-progression (P = .002); higher tumor mutational burden was unfavorable for survival (P = .026).Conclusions
Except for the overall unfavorable prognostic effect of PIK3CA mutations in trastuzumab-treated MBC, our exploratory findings indicate that the outcome of patients with R-MBC is related to patient benefit from the preceding adjuvant chemotherapy and provide initial evidence that tumor mutational burden may be related to prognosis in dn-MBC, which is of potential clinical relevance and merits further investigation. 相似文献53.
Konstantinos N. Lazaridis 《Journal of gastrointestinal surgery》2008,12(3):417-419
Sclerosing cholangitis represents a spectrum of chronic biliary diseases that either has an unknown etiology (i.e., primary)
or is caused by identifiable insults to the biliary tree (i.e., secondary). To date, the epidemiology of primary sclerosing
cholangitis has been appraised; however, its etiology continues to be unclear. In contrast, the etiology of secondary sclerosing
cholangitis is always known, but the epidemiology of this clinical entity is difficult to study.
This paper was originally presented as part of the SSAT/AHPBA Joint Symposium on Sclerosing Cholangitis at the SSAT 48th Annual
Meeting, May 2007, in Washington, DC. The other articles presented in the symposium were Schulick RD, Primary Sclerosing Cholangitis: Detection of Cancer in Strictures; Ahrendt SA, Surgical Approaches to Strictures in Primary Sclerosing Cholangitis; and Chapman WC, Primary Sclerosing Cholangitis: Role of Liver Transplantation. 相似文献
54.
55.
N. Melas A. Saratzis N. Saratzis J. Lazaridis D. Psaroulis K. Trygonis D. Kiskinis 《European journal of vascular and endovascular surgery》2010,39(4):429-435
ObjectiveTo evaluate the proximal and distal (iliac) fixation of seven self-expanding endografts, used in the endovascular treatment (EVAR) of abdominal-aortic aneurysm (AAA), by measuring the displacement force (DF) necessary to dislocate the devices from their fixation sites.MethodsA total of 20 human cadaveric aortas were exposed, left in situ and transected to serve as fixation zones. The Anaconda, EndoFit aorto-uni-iliac, Endurant, Powerlink, Excluder, Talent and Zenith stent grafts were deployed and caudal force was applied at the flow divider, through a force gauge. The DF needed to dislocate each device ≥ 20 mm from the infrarenal neck was recorded before and after moulding-balloon dilatation. Cephalad force was similarly applied to each iliac limb to assess distal fixation before and after moulding-balloon dilatation.ResultsEndografts with fixation hooks or barbs displayed a significantly higher DF necessary to dislocate the proximal portion compared with devices with no such fixation modalities (p < 0.001). Balloon dilatation produced a significant increase in DF in both devices with (p < 0.001) or without (p = 0.003) hooks or barbs. Suprarenal support did not enhance proximal fixation (p = 0.90). Balloon dilatation significantly increased the DF necessary to dislodge the iliac limbs (p = 0.007).ConclusionsDevices with fixation hooks displayed higher proximal fixation. Moulding-balloon dilatation increased proximal and distal fixation. Suprarenal support did not affect proximal fixation. 相似文献
56.
Kraft SK Lazaridis EN Qiu C Clark CM Marrero DG 《Journal of general internal medicine》1999,14(2):88-97
OBJECTIVE: To describe the practices of Indiana primary care physicians related to diabetic nephropathy screening and management. DESIGN: Cross-sectional, observational. SETTING: The state of Indiana. PARTICIPANTS: Active primary care physicians (defined as general internists, family practitioners, and general practitioners) in Indiana who provided care for diabetic patients at the time of the survey (n = 1,018) MEASUREMENTS AND MAIN RESULTS: Practice patterns relevant to microalbuminuria and overt albuminuria screening and management were assessed along two dimensions: the percentage of patients to whom the practices were applied and the frequency with which the practices were performed. Of 1,141 physicians who responded to the survey, 1,018 were eligible for analysis. Eighty-six percent of physicians reported screening more than half of their patients with type 1 diabetes for overt albuminuria, as did 82% of physicians for their patients with type 2 diabetes. Only 17% of physicians indicated performing microalbuminuria testing on more than half of their type 1 patients. Angiotensin-converting enzyme inhibitor agents were used frequently to treat abnormal urinary albumin excretion when hypertension was present, but less often when hypertension was absent. Physician specialty, year of graduation from medical school, practice location, and familiarity with the results of the Diabetes Control and Complications Trial were significant predictors of screening and treatment practice patterns. CONCLUSIONS: Primary care physicians report practices that allow them to detect overt albuminuria but not microalbuminuria. Angiotensin-converting enzyme inhibitors are frequently used by physicians who test for microalbuminuria, but efforts to increase the detection of early renal damage are needed so that these agents and other therapeutic strategies may be employed at the earliest opportunity. 相似文献
57.
Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties 总被引:1,自引:0,他引:1 下载免费PDF全文
Lazaridis KN Tietz P Wu T Kip S Dawson PA LaRusso NF 《Proceedings of the National Academy of Sciences of the United States of America》2000,97(20):11092-11097
Bile secretion involves the structural and functional interplay of hepatocytes and cholangiocytes, the cells lining the intrahepatic bile ducts. Hepatocytes actively secrete bile acids into the canalicular space and cholangiocytes then transport bile acids in a vectorial manner across their apical and basolateral plasma membranes. The initial step in the transepithelial transport of bile acids across rat cholangiocytes is apical uptake by a Na(+)-dependent bile acid transporter (ASBT). To date, the molecular basis of the obligate efflux mechanism for extrusion of bile acids across the cholangiocyte basolateral membrane remains unknown. We have identified an exon-2 skipped, alternatively spliced form of ASBT, designated t-ASBT, expressed in rat cholangiocytes, ileum, and kidney. Alternative splicing causes a frameshift that produces a 154-aa protein. Antipeptide antibodies detected the approximately 19 kDa t-ASBT polypeptide in rat cholangiocytes, ileum, and kidney. The t-ASBT was specifically localized to the basolateral domain of cholangiocytes. Transport studies in Xenopus oocytes revealed that t-ASBT can function as a bile acid efflux protein. Thus, alternative splicing changes the cellular targeting of ASBT, alters its functional properties, and provides a mechanism for rat cholangiocytes and other bile acid-transporting epithelia to extrude bile acids. Our work represents an example in which a single gene appears to encode via alternative splicing both uptake and obligate efflux carriers in a bile acid-transporting epithelial cell. 相似文献
58.
Opinion statement
相似文献
– | Primary biliary cirrhosis (PBC) is one of the most common chronic cholestatic liver diseases affecting the adult population. |
– | The clinical presentation of PBC can be diverse, ranging from the presymptomatic individual to the patient with advanced liver disease. The initial evaluation to establish the diagnosis, and the appropriate followup, are very important in the lifelong management of these patients. |
– | The primary medical treatment in PBC should focus on reducing the rate of disease progression. To this extent, ursodeoxycholic acid has been extensively evaluated and proven to improve liver biochemistries and survival in patients with PBC. |
– | The secondary medical management in PBC should address the treatment of complications of chronic cholestasis, hepatic cirrhosis, and failure. |
– | Liver transplantation remains the only established therapeutic approach in treating patients with end-stage PBC and its associated complications. |
59.
Nguyen DL Juran BD Lazaridis KN 《Best Practice & Research: Clinical Gastroenterology》2010,24(5):647-654
Primary biliary cirrhosis (PBC) is an idiopathic chronic autoimmune liver disease that primarily affects women. It is believed that the aetiology for PBC is a combination between environmental triggers in genetically vulnerable persons. The diagnosis for PBC is made when two of the three criteria are fulfilled and they are: (1) biochemical evidence of cholestatic liver disease for at least 6 month's duration; (2) anti-mitochondrial antibody (AMA) positivity; and (3) histologic features of PBC on liver biopsy. Ursodeoxycholic acid (UDCA) is the only FDA-approved medical treatment for PBC and should be administered at a recommended dose of 13-15 mg/kg/day. Unfortunately despite adequate dosing of UDCA, approximately one-third of patients does not respond adequately and may require liver transplantation. Future studies are necessary to elucidate the role of environmental exposures and overall genetic impact not only in the development of PBC, but on disease progression and variable clinical response to therapy. 相似文献
60.
M. G. Pramateftakis G. Vrakas P. Hatzigianni T. Tsachalis I. Matzoros E. Christoforidis D. Raptis G. Roidos C. Lazaridis 《Techniques in coloproctology》2010,14(1):57-80